Clinical Trial Update: XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma [Phase 1]

View source ↗

Summary

Phase 1 trial update for XL888 in combination with Vemurafenib and Cobimetinib in unresectable, BRAF-mutated stage III/IV melanoma; the study is currently activ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Skin Cancer

Drugs mentioned

• Cobimetinib (cobimetinib)
• Vemurafenib (vemurafenib)
• XL888

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Melanoma, Skin Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING